Editorial: EBV and human cancer

Experimental and Molecular Medicine

Volumn 47, Issue 1, 2015, Pages

  Ko, Young Hyeh ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ASPARAGINASE;

AGGRESSIVE NK CELL LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER PROGNOSIS; CELL TRANSFORMATION; DISEASE ASSOCIATION; DNA METHYLATION; EDITORIAL; ENVIRONMENTAL FACTOR; EPIGENETICS; EPSTEIN BARR VIRUS INFECTION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; NONHUMAN; STOMACH ADENOCARCINOMA; T CELL LEUKEMIA; VIRAL GENETICS; VIRUS CARCINOGENESIS; VIRUS LATENCY; COMPLICATION; EPSTEIN BARR VIRUS; NEOPLASMS; PHYSIOLOGY;

HUMAN HERPESVIRUS 4;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NEOPLASMS;

EID: 84928005177     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.109     Document Type: Editorial

References (33)

1. Kushekhar K, van den Berg A, Nolte I, Hepkema B, Visser L, Diepstra A. Genetic associations in classical Hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms. Cancer Epidemiol Biomarkers Prev 2014;23:1-11.
2. Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 2014;26:22-29.
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.
4. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014;4:pii: a014282.
5. Bellan C, Amato T, Piccaluga PP, Abate F, De Falco G, Ambrosio MR et al. The pressure of the antigens in the pathogenesis of BL. Evidence from NGS analysis of BCR. 17th Meeting of the European Association for Haematopathology; 22-27 October 2014; Istanbul. Abstract (OP-LYMP-15), p 61.
6. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1(7335):702-703.
7. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005;79:13993-14003.
8. Song YJ, Kang MS. Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation. Virus Genes 2010;41:174-180.
9. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K et al. Agerelated Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009;113:2629-2636.
10. Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011;117:4726-4735.
11. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosía SG, Mazorra F et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012;25:968-982.
12. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013;122:328-340.
13. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC et al. Prevalence and clinical implications of Epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 2014;20:2338-2349.
14. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virusassociated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009;20:1472-1482.
15. Park S, Ko YH. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders. J Dermatol 2014;41:29-39.
16. Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012;120:4795-4801.
17. Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol 2014;99:227-239.
18. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009;137:824-833.
19. Kim J, Lee HS, Bae SI, Lee YM, Kim WH. Silencing and CpG island methylation of GSTP1 is rare in ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res 2005;25:4013-4019.
20. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013;424:53-65.
21. Gulley ML, Fan H, Elmore SH. Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting. J Mol Diagn 2006;8:589-597.
22. Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ER et al. Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect Agent Cancer 2010;5:27.
23. Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL et al. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 2012;57:1887-1898.
24. Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K et al. Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer 2012;7:21.
25. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/gamma (c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-3182.
26. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008;198:673-682.
27. Kuwana Y, Takei M, Yajima M, Imadome K, Inomata H, Shiozaki M et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS ONE 2011;6:e26630.
28. Fujiwara S. Reproduction of Epstein-barr virus infection and pathogenesis in humanized mice. Immune Netw 2014;14:1-6.
29. Imadome K, Yajima M, Arai A, Nakazawa A, Kawano F, Ichikawa S et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 2011;7:e1002326.
30. Kwon JM, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006;85:463-468.
31. Park S, Lee J, Ko YH, Han A, Jun. HJ, Lee SC et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
32. Tse E, Kwong YL. Treatment algorithms for mature T-cell and natural killercell neoplasms. Future Oncol 2011;7:1101-1112.
33. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-4416.